Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romidepsin in Recurrent, Platinum-Sensitive Ovarian or Peritoneal Cancer
NCT00091195Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romidepsin in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Primary endpoints: Objective Response Rate up to 5 years, Toxicity assessed by CTCAE version 3.0 up to 5 years and 2 more. Started Sep 2004; status: terminated.
02
Drugs
romidepsin
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00091195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091195.